[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,108,0,25,[9,46,74,101,132,155,199,223,254,278,307,351,373,396,418,463,491,545,569,599,666,693,717,740,808],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100592308","177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iodine-non-responsive-oncocytic-hurthle-cell-thyroid-cancer-100592308",false,"NCT06991738","177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","Phase 1\u002F2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged 18 years or older.\n* Metastatic RAI-non-responsive and\u002For RAI-non-avid oncocytic (Hurthle cell) thyroid cancer.\n* Progressive disease by RECIST 1.1 criteria, with or without symptoms within the last 12 months. This applies to patients with non-measurable disease by RECIST 1.1 criteria, who will be eligible if they have evidence of progression as defined by the development of new lesions within the last 12 months.\n* High expression of SSTR2 in at least one metastatic lesion as documented by 68Ga-DOTATATE PET\u002FCT with SUVmax \\> SUVmax of the liver consistent with Krenning score of \\>2 or SUVmax \\>= 13 based on scan performed within 12 weeks of anticipated enrollment.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnant or breastfeeding.\n* NET\u002FPET score of 5 by imaging with 68Ga-DOTATATE PET\u002FCT and 18FDG-PET\u002FCT and defined more than 2 lesions that are SSTR2 negative but 18FDG positive and\u002For more than 2 lesions that have significantly higher uptake of 18FDG than 68Ga-DOTATATE\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-EB-TATE as assessed from medical record.\n* Patient weight \\> 500 lbs. (due to the PET scanner table limit).\n* Inability to tolerate at least one modality of diagnostic anatomic imaging, such as CT or MRI.\n* Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 4 weeks or 4 half-lives (whichever is longer), before the first administration of study drug.\n* Previous surgery \\\u003C 6 weeks prior to the start of participation in this study, or participant has not fully recovered from major surgery, or has suffered significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 3 months after the last dose of study drug.\n* Life expectancy \\\u003C 6 months as assessed by the treating physician.\n* Karnofsky performance status scale \\\u003C 70%.\n* Inability or unwillingness to use adequate contraception prior to study entry and for the duration of study participation, including follow-up (7 months after the last dose of study drug for women and 4 months for men). The adequate contraception consists of intrauterine device, contraceptive implant, hormonal contraception or a double-barrier method. If the patient is status post tubal ligation, status post hysterectomy and\u002For oophorectomy, or their male partners are status post vasectomy, no additional method of contraception is required.\n* Deteriorated renal function, as indicated by a creatinine clearance \\\u003C60 mL\u002Fmin calculated by the Cockcroft-Gault Equation. The calculated creatinine clearance can be confirmed by measured creatinine clearance.\n* Having only one functional kidney, due to potential nephrotoxicity.\n* Patients who have had any prior EBRT dose to either kidney.\n* Deteriorated bone marrow function, as indicated by:\n\n  * Hemoglobin (Hb) \\\u003C 8.0 g\u002FdL\n  * White blood cell (WBC) \\\u003C 2 x10\\^3\u002FuL\n  * Absolute neutrophil count (ANC) \\\u003C 1.0 x 10\\^3\u002FL\n  * Platelets \\\u003C100 x 10\\^3\u002FmicroL\n* Deteriorated liver function, as indicated by one or more of the following:\n\n  * International normalized ratio (INR) \\> 2.0 for patients that are not on Coumadin\n  * Prothrombin time (PTT) \\> 2 x ULN\n  * Total bilirubin \\> 3 mg\u002FdL\n  * Serum albumin \\\u003C 3.0 g\u002FdL unless prothrombin time is within the normal range\n  * Alanine aminotransferase (ALT) \\> 3 x ULN\n  * Aspartate aminotransferase (AST) \\> 3 x ULN.\n* Previous local therapy \\\u003C4 weeks prior to study entry.\n* Extended QTc interval above 480 ms confirmed by 2 ECGs. If the first ECG conducted at the screening visit shows extended QTc interval, potential participants will be asked to repeat an ECG within 30 days to confirm. The second ECG can be conducted at NIH CC or at their outside provider, at their potential expense.\n* Toxicities from prior therapies that have not resolved to grade 1 or grade 0 excluding dry mouth syndrome from previous RAI and grade 2 anemia\u002Fleukopenia as Hgb\\>=8 g\u002Fdl, WBC \\>=2 x10\\^3\u002FuL and ANC \\>= 1.0 x 10\\^3 are acceptable for enrollment.\n* Active and clinically significant bacterial, fungal, or viral infection, including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness. Radiolabeled ligands may affect the immune response, so people with active and clinically significant infections may become too immunocompromised through participation in this study.\n* Known brain metastases and\u002For carcinomatous meningitis unless these metastases have been treated and stabilized.\n* Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Prior external beam radiation therapy involving \\>25% of the bone marrow.\n* Unmanageable urinary incontinence rendering the administration of 177Lu-DOTA-EB-TATE unsafe.\n* Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence.\n* Is unwilling or unable to establish care with a local provider outside of NIH CC\n* Inability to understand or unwilling to sign a written informed consent document.","ALL","18 Years","100 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nOncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells.\n\nObjective:\n\nTo test a radioactive drug (177LuDOTA-EB-TATE) in people with HTC.\n\nEligibility:\n\nPeople aged 18 years and older with HTC. The HTC must have failed to respond to conventional radioactive treatment; it must also have spread to other parts of the body.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood tests. They will have imaging scans and a test of their heart function.\n\n177LuDOTA-EB-TATE is infused into a vein. Participants will receive 4 infusions spaced 8 to 12 weeks apart. They will stay in the hospital for 4 to 10 days after each infusion. During and after each infusion, participants will remain in a lead-lined room until their radiation levels go down; this usually takes about 24 hours.\n\nParticipants will have 4 to 6 follow-up visits in the weeks after each infusion. Procedures will vary at each visit, but may include more imaging scans; blood and urine tests; and tests of heart function. Participants will have 2 single-photon emission computerized tomography (SPECT) scans. SPECT scans show where the study drug is sticking to tumors or maybe other parts of their body. They will lie on a table while a machine rotates around them. Participants will fill in questionnaires about how their thyroid condition affects their life.\n\nParticipants will have follow-ups visits for 5 years after their last study treatment.",[29],"Thyroid Cancer",[29,31,32],"H(SqrRoot) rthle cell thyroid cancer","177Lu-DOTA-EB-TATE","NOT_YET_RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":22},"2026-08-26",{"date":41,"type":22},"2032-08-01",{"name":43,"class":44},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100652759","phase-2-selective-coverage-versus-comprehensive-coverage-radiotherapy-in-poorly-differentiated-and-anaplastic-thyroid-cancer-100652759","NCT07777536","Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer","Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer: A Randomized, Controlled, Non-inferiority, Phase 2 Study","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Pathologically confirmed as ATC, thyroid cancer containing ATC components, PDTC (in accordance with Turin criteria), or other thyroid cancers with poorly differentiated components, and the MDT considers the biological behavior similar to PDTC.\n* Evaluated by the MDT and proposed to receive external beam radiotherapy, including postoperative R0\u002FR1, R2 gross residual, inoperable local lesion, and local recurrence.\n* ECOG performance status 0-2\n* expected survival ≥ 3 months\n* major organ functions can meet the requirements for radiotherapy and the proposed systemic treatment.\n* The subject voluntarily participates in the study and signs a written informed consent form, willing to follow up according to the protocol and fill in the quality of life scale.\n\nExclusion Criteria:\n\n* Has received radiotherapy to the head and neck or upper mediastinum region in the past, and the target area of this study overlaps significantly with it, and the normal tissue limit cannot be met.\n* Has severe uncontrolled infections, active bleeding, unaddressed airway crises, severe dysfunction of the heart, lungs, liver, kidneys or other diseases that cannot be safely treated with radiotherapy.\n* Pregnant or lactating women; women of childbearing age who do not agree to take effective contraceptive measures.\n* Has other active malignant tumors within 5 years or simultaneously (excluding cured localized tumors such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, etc.)\n* Cannot complete radiotherapy fixation, simulation positioning or follow-up imaging assessment.\n* Other situations that the researcher deems unsuitable for participation in this study.",{"count":54,"type":22},72,[26],"To explore the efficacy and safety of selective coverage radiotherapy in poorly differentiated and anaplastic thyroid cancer",[29],[59,60,61,62,63],"poorly differentiated thyroid cancer","anaplastic thyroid cancer","selective coverage radiotherapy","locoregional control","radiotherapy-related toxicity","RECRUITING","2026-08-19",{"date":34,"type":37},{"date":68,"type":37},"2026-08-12",{"date":70,"type":22},"2032-07-31",{"name":72,"class":73},"Fudan University","OTHER",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":4,"leadSponsor":100,"locationsCount":45},"100054237","studies-on-tumors-of-the-thyroid-100054237","NCT00001160","Studies on Tumors of the Thyroid","Studies on Thyroid Nodules and Thyroid Cancer","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Male or female, adults or children \\>= 6 months+.\n2. Patients with known or suspected thyroid nodules and\u002For thyroid cancer.\n3. At risk family members of patients who have a genetic susceptibility to developing thyroid cancer.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma requiring intervention before thyroid cancer is addressed.","6 Months","98 Years",{"count":84,"type":22},2500,"OBSERVATIONAL","Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer.\n\nThe main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.",[88,89,90,29,91],"Hurthle Cell Thyroid Cancer","Tall Cell Variant Thyroid Cancer","Follicular Thyroid Cancer","Papillary Thyroid Cancer",[93,94,95,96],"Thyroid Fine Needle Biopsy","Radioiodine","Dosimetry","Natural History",{"date":34,"type":37},{"date":99,"type":37},"1977-06-01",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":45},"100625855","postoperative-hypocalcemia-after-thyroidectomy-100625855","NCT07428057","Postoperative Hypocalcemia After Thyroidectomy","A Ten-Year Cohort Study of Clinical and Surgical Predictors for Hypocalcemia Post-Thyroidectomy","Inclusion Criteria:\n\n* Adult patients aged 18 years or older at time of surgery\n* Underwent thyroidectomy at Minia University Hospital\n* Availability of medical records with complete surgical and postoperative data\n* Documented serum calcium levels measured postoperatively\n* Minimum follow-up of 6 months postoperatively or documented outcome status\n\nExclusion Criteria:\n\n* Age less than 18 years at time of surgery\n* Preoperative hypocalcemia (serum calcium \\\u003C8.0 mg\u002FdL or ionized calcium \\\u003C1.0 mmol\u002FL)\n* Pre-existing parathyroid disorders (primary hyperparathyroidism, hypoparathyroidism, secondary or tertiary hyperparathyroidism)\n* Chronic kidney disease Stage 3 or higher (estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Malabsorption syndromes affecting calcium metabolism (celiac disease, inflammatory bowel disease,short bowel syndrome)\n* Concurrent planned parathyroidectomy\n* History of neck irradiation\n* Chronic use of medications significantly affecting calcium metabolism (bisphosphonates, denosumab,cinacalcet, chronic corticosteroids)\n* Incomplete medical records lacking essential data including surgical details, postoperative calcium levels,or follow-up data\n* Patients lost to follow-up before 6-month endpoint without documented outcome status","75 Years",{"count":110,"type":22},600,"This retrospective cohort study investigates predictors of postoperative hypocalcemia following thyroidectomy procedures at Minia University Hospital over a 10-year period (2014-2024). Postthyroidectomy hypocalcemia is one of the most common complications of thyroid surgery, affecting 20-50% of patients. The study aims to identify demographic, clinical, laboratory, and surgical factors associated with the development of both transient and permanent hypocalcemia. Results will inform risk stratification, patient counseling, and perioperative management strategies.",[113,114,115,29,116],"Thyroid Nodule","Thyroid Dysfunction","Hypocalcemia","Postoperative Complications",[118,119,120,121,122],"Thyroidectomy","Postoperative hypocalcemia","Hypoparathyroidism","Parathyroid gland injury","Total thyroidectomy","2026-08-16",{"date":125,"type":37},"2026-08-18",{"date":127,"type":37},"2026-03-04",{"date":129,"type":22},"2027-01-01",{"name":131,"class":73},"Minia University",{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100350346","phase-2-the-use-of-124-i-petct-whole-body-and-lesional-dosimetry-in-differentiated-thyroid-cancer-100350346","NCT03841617","The Use of 124-I-PET\u002FCT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","* INCLUSION CRITERIA:\n* Patients with established thyroid cancer diagnosis based on the pathology report reviewed at the National Institutes of Health, who:\n\n  * underwent total thyroidectomy plus or minus neck lymph node dissection as clinically indicated,\n  * are presenting with known per structural imaging (US neck, CT or MRI neck\u002Fchest\u002Fabdomen\u002Fpelvis) persistent\u002Frecurrent disease either locally advanced or presenting with distant metastases; or\n  * are presenting with suspected persistent\u002Frecurrent locoregional or distant metastases based on the high risk features such as advanced tumor per pathology report (tumor size \\>4 cm, exrathyroidal extension, higher risk pathology such as tall cell, columnar cell, poorly differentiated variant, follicular thyroid cancer with gross vascular invasion, positive margins after the surgery, bulky lymphadenopathy in the central and\u002For lateral neck), detectable\u002Fincreasing baseline\u002Fsuppressed thyroglobulin (Tg) level or detectable\u002Fincreasing anti-Tg antibody titers if anti-Tg antibodies are present.\n  * are either RAI -naive or requiring repeated RAI therapy for locally advanced disease or distant metastases or underwent therapy with BRAF inhibitor (dabrafenib or vemurafenib\\*) or selumetinib\\*\\* for at least 4 weeks that may re-induce RAI uptake.\n  * Underwent imaging with either a CT or MRI of the brain and spine with gadolinium contrast to screen for the brain\u002Fspine metastases.\n\n    * Age greater than or equal to 18 years of age.\n    * 24 hour urine iodine excretion of less than or equal to 150 micro grams\u002F24 hour.\n\n      * BRAF inhibitors are recommended by 2021 NCCN guidelines as one of the management options for BRAF mutant tumors(13,14)\n\n        * Selumetinib has an FDA orphan drug designation for adjuvant treatment of metastatic thyroid cancer to re-induce RAI uptake\n\nEXCLUSION CRITERIA:\n\n-Patients with RAI-non avid disease documented by negative post-therapy whole body scans performed after previous RAI treatments and not subjected to re-differentiation therapy.\n\n* Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma, severe depression which might be exacerbated by thyroid hormone withdrawal.\n* Patients with spinal or brain metastases as they are at risk of TSH-stimulation induced swelling of metastatic lesions leading to potentially detrimental side effects. These patients will be evaluated per the standard of care protocol 77-DK-0096.\n\n  * Pregnant or lactating women per self report.\n  * Adults who are incapable of providing informed consent.","90 Years",{"count":140,"type":22},30,[26],"Study rationale\n\nHigh risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation. There are two methods of TSH stimulation endogenous by thyroid hormone withdrawal (THW) leading to hypothyroidism and exogenous by injection of human recombinant TSH (rhTSH Thyrogen). The appropriate 131-I activity utilized for treatment is either based on empiric fixed dosage choice or individually determined activity based on 131 I dosimetric calculations. Although dosimetry utilizing radioactive iodine isotope 131 I enables calculation of maximum safe dose, it does not estimate the tumoricidal activity necessary to destroy the metastatic lesions. The alternative radioactive isotope of iodine -124 I, used for positron emission tomography (PET) imaging, might be used for calculation not only the maximum safe131 I dose, but also to predict the absorbed dose in the metastatic lesions.\n\nStudy objectives\n\nThe primary objective of this study is to compare the 124 I -PET\u002FCT lesional and whole body dosimetry in each individual patient with metastatic radioiodine (RAI)-avid thyroid cancer under preparation with rhTSH and THW. The secondary objective is to evaluate the predicted by PET\u002FCT lesional uptake with the early response to therapy.\n\nStudy design\n\nThis is a phase 2 pilot prospective cohort study comparing the lesional and whole body dosimetry within each patient undergoing exogenous (rhTSH) and endogenous (THW) TSH stimulation and followed for 5 years.\n\nInterventions\n\nEach study participant will undergo rhTSH and THW-aided 124 I-PET\u002FCT dosimetric evaluations and will be subsequently treated with THW-aided RAI activity based on dosimetric calculations enabling maximum safe dosage. The patients will be followed in 12+\u002F-3 months intervals for 5 years.\n\nSample size and population\n\nThis pilot study will include 30 patients with high risk differentiated thyroid cancer presenting with distant and\u002For loco-regional metastases.\n\n...",[29],[29,145,146,94,147],"PET\u002FCT","124-I","Metastases","2026-08-15",{"date":125,"type":37},{"date":151,"type":37},"2019-07-29",{"date":153,"type":22},"2035-11-01",{"name":43,"class":44},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":180,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":198},"100480603","phase-1-a-study-to-learn-about-the-study-medicine-called-pf-07799544-as-monotherapy-or-in-combination-in-people-with-advanced-solid-tumors-100480603","NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","A PHASE 1A\u002FB OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS","Phase 1b Inclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor (excluding colorectal cancer)\n* Measurable disease by RECIST version 1.1\n* Evidence of a BRAF V600 mutation\n* Prior therapy per tumor cohort\n* Adequate organ function per protocol\n\nPhase 1b Exclusion Criteria:\n\n* Other active malignancy within 3 years\n* Presence of leptomeningeal disease\n* History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease\n* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)\n* Active gastrointestinal disease as defined per protocol\n* History of interstitial lung disease as defined per protocol","16 Years",{"count":164,"type":22},124,[25],"The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).\n\nPhase 1a is no longer open for enrollment. In Phase1b (noted as \"this study\"), we are seeking participants who have:\n\n* a solid tumor which is metastatic or recurrent (excluding colorectal cancer)\n* tumor with the mutation (abnormal gene) called \"BRAF V600\"\n* received required prior treatment for cancer per cohort assigned.\n\nAll participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.\n\nParticipants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.",[168,169,29,170,171,172,173,174,175,176,177,178,179],"Melanoma","Glioma","Non-Small Cell Lung Cancer","Malignant Neoplasms","Brain Neoplasms","Advanced or Metastatic Solid Tumors","HGG","LGG","Low Grade Glioma","High Grade Glioma","Differentiated Thyroid Cancer","NSCLC (Non-small Cell Lung Cancer)",[181,182,183,184,185,186,187],"solid tumors","BRAF","advanced solid tumors","B-Raf","MAPK","neoplasms","BRAF V600","2026-08-13",{"date":190,"type":37},"2026-08-14",{"date":192,"type":37},"2022-11-30",{"date":194,"type":22},"2029-06-18",{"name":196,"class":197},"Pfizer","INDUSTRY",83,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":207,"targetDuration":209,"studyType":85,"phases":4,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100597516","prevalence-and-predictors-of-incidental-thyroid-carcinoma-in-patients-with-graves-disease-undergoing-thyroidectomy-100597516","NCT07059507","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy: A Prospective Study.","GD","Inclusion Criteria:\n\n* Age 18 years or older.\n* Confirmed diagnosis of Graves' disease based on clinical features (e.g., diffuse goiter, ophthalmopathy if present) and biochemical evidence (suppressed TSH, elevated free T4 and\u002For T3) and\u002For positive TSH receptor antibody (TRAb) test.\n* Indication for total thyroidectomy for Graves' disease, based on established guidelines:\n\nRelapse or persistence of hyperthyroidism after a course of antithyroid drugs (ATDs).\n\nIntolerance or adverse reaction to ATDs. Patient preference for surgery over radioactive iodine (RAI) or long-term ATDs. Presence of a large goiter causing compressive symptoms. Coexisting suspicious thyroid nodule(s) on preoperative evaluation. Moderate to severe active Graves' ophthalmopathy where RAI is relatively contraindicated.\n\n* Patient is scheduled for total thyroidectomy (near-total or subtotal thyroidectomy patients will be excluded).\n* Ability and willingness to provide written informed consent.\n* Ability to understand study procedures and requirements.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Previous thyroid surgery.\n* Previous neck irradiation.\n* Preoperative diagnosis of thyroid malignancy confirmed by fine-needle aspiration (FNA) cytology (Bethesda V or VI) , the focus is on incidental carcinoma.\n* Inability to provide informed consent (e.g., due to cognitive impairment).\n* Patients undergoing thyroidectomy primarily for reasons other than Graves' disease (e.g., primary indication is large non-toxic MNG).\n* Patients undergoing less than total thyroidectomy (e.g., lobectomy, subtotal thyroidectomy).",{"count":208,"type":22},280,"1 Month","The prevalence of incidental thyroid cancer (ITC) in Graves' Disease (GD) patients undergoing thyroidectomy appears higher than historically believed, potentially exceeding 10% in large contemporary series, although significant variability exists. The presence of nodules is a strong predictor, while the roles of age, sex, and BMI require clarification. Most ITCs are papillary thyroid microcarcinoma(PTMCs) with generally favorable prognoses, but concerns about aggressiveness persist.\n\nThe purpose of the present study is to accurately evaluate the prevalence of incidental thyroid carcinoma (ITC), including microcarcinomas, in a prospectively enrolled cohort of patients undergoing total thyroidectomy for Graves' disease, utilizing standardized pathological examination protocols and secondary outcomes including predictors and histopathological characteristics.",[29,212],"Graves Disease",[214],"Incidental thyroid cancer","2026-08-08",{"date":217,"type":37},"2026-08-11",{"date":219,"type":37},"2025-07-15",{"date":221,"type":22},"2027-01-15",{"name":131,"class":73},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100647086","pralsetinib-ddi-study-in-patients-with-advanced-or-metastatic-solid-tumors-100647086","NCT07704658","Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors","A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol\u002FNorethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Must be willing and able to participate and comply with all study requirements and to provide signed and dated written informed consent\n* Adult male or female ≥ 18 years of age at the time of signing the informed consent form.\n* Must have a body mass index (BMI) ≥ 18 and ≤ 32 kg\u002Fm² and a minimum body weight of 50 kg at screening.\n* Must have an Eastern Cooperative Oncology Group performance status ≤ 2.\n* Must have recovered from the non-hematologic toxic effects of prior treatment to Grade ≤ 1, or baseline value (excluding infertility, alopecia, or Grade 1 neuropathy)\n* Must have a confirmed diagnosis of advanced or metastatic solid tumor that has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.\n* Must have adequate organ function, defined by the following:\n\n  1. Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹\u002FL.\n  2. Platelet count ≥ 75 × 10⁹\u002FL.\n  3. Hemoglobin ≥ 9 g\u002FdL.\n  4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with known liver metastases.\n  5. Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in patients with Gilbert syndrome).\n  6. Creatinine clearance ≥ 40 mL\u002Fmin using the Cockcroft-Gault equation.\n  7. Serum phosphorus ≤ 5.5 mg\u002FdL.\n  8. International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) within normal laboratory limits.\n* Must be at least 4 weeks from major surgery, radiotherapy, chemotherapy, immunotherapy, kinase\u002Ftargeted therapy, or gene therapy prior to the first dose of study treatment and recovered from treatment-related toxicities to ≤ Grade 1 (excluding alopecia). Must be ≥ 6 weeks since last treatment if they received a long-acting agent such as a nitrosourea, mitomycin, or monoclonal antibodies. In general, a treatment interval of two half-lives should be considered and discussed with the Sponsor. (Concurrent cancer therapy of any type is not permitted).\n* Female patients may participate if they are not of childbearing potential (e.g., surgically sterile or postmenopausal).\n* Male patients with female partners of childbearing potential must agree to use highly effective contraception during study treatment and for 90 days after the last dose of study treatment.\n* Male patients must refrain from sperm donation during study treatment and for 90 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, electrocardiogram (ECG), or laboratory tests at screening that, in the investigator's judgment, are likely to interfere with the objectives of the trial or the safety of the patient.\n* Surgery (e.g., gastric bypass) or medical condition that may significantly affect absorption of study medications, as judged by the investigator.\n* History of pneumonitis within the last 12 months.\n* History of active or latent tuberculosis (TB), regardless of treatment history, or a positive screening test for latent Mycobacterium tuberculosis infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat testing or by a purified protein derivative (PPD) skin test.\n* Serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment, or any active infection that, in the opinion of the investigator, could impact patient safety (e.g., COVID-19 or influenza).\n* Clinically significant, uncontrolled cardiovascular disease, including:\n\n  1. New York Heart Association (NYHA) Class III or IV congestive heart failure.\n  2. Myocardial infarction or unstable angina within the previous 6 months, clinically significant uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (e.g., second- or third-degree heart block).\n  3. Uncontrolled hypertension (i.e., mean systolic blood pressure ≥180 mmHg and\u002For diastolic blood pressure ≥110 mmHg on 3 repeated measurements) or clinically significant hypotension (i.e., systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C50 mmHg) or severe episodes of orthostatic hypotension.\n  4. History of prolonged QT syndrome or torsades de pointes, or familial history of long QT syndrome.\n  5. QTcF ≥470 ms on at least 2 ECGs performed \\>30 minutes apart.\n* Central nervous system (CNS) metastases or primary CNS tumor.\n* Use of systemic corticosteroids within 4 weeks prior to first dose of study treatment.\n* More than 30 Gy of radiotherapy to the lung within 6 months prior to check-in.\n* History of multiple and\u002For severe allergies to drugs or foods, or history of severe anaphylactic reaction.\n* Use of prohibited medications or procedures\n* Medical conditions, treatments, or underlying diseases that constitute contraindications to the use of study substrates or probe drugs\n* Ingestion of alcohol within 72 hours prior to first study drug administration and during the study period.\n* Participation in another investigational drug trial within 30 days prior to study drug administration (or within 5 half-lives of the investigational drug, whichever is longer) or exposure to more than 3 investigational agents within 12 months prior to study drug administration.\n* Positive serology for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening (a negative PCR test overrides a positive serology).\n* Positive human immunodeficiency virus (HIV) test at screening.\n* Positive urine drug screen (unless attributable to concomitant medication) or positive alcohol breath test at screening and\u002For Day -1.\n* Patients who are legally incapacitated, have limited legal capacity, or are otherwise considered vulnerable.\n* Female patients who are pregnant or breastfeeding.\n* Patients who plan to become pregnant or father a child (including ova or sperm donation) during the study or within 3 months after the last dose of study drug.\n* Known allergy or history of hypersensitivity to study drug(s) or their excipients.\n* Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and\u002For CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.\n* Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and\u002For CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.\n* History of or active clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatologic, hematologic, or other disorder that, in the investigator's judgment, could interfere with study participation or the absorption, metabolism, or excretion of study treatment.\n* History of prior second malignancy unless disease-free for ≥ 12 months or considered surgically cured. Patients with nonmelanoma skin cancers or with carcinomas in situ at any time following curative intent surgery and low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected are also eligible.",{"count":231,"type":22},12,[233],"PHASE4","An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors",[179,29,236,237],"Solid Tumor Malignancies","Advanced Malignancies",[239,240,241,242,243,244],"Oncology","Drug-Drug Interactions","Medical Oncology","RET Fusion Positive","RET Gene Mutation","Pharmacokinetic (PK)","2026-08-07",{"date":247,"type":37},"2026-08-10",{"date":127,"type":37},{"date":250,"type":22},"2027-08-30",{"name":252,"class":197},"Rigel Pharmaceuticals",2,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":45},"100572870","renovated-prediction-model-for-difficult-transoral-and-submental-endoscopic-thyroidectomy-100572870","NCT06738888","Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy","A Functional-oriented Modification of TOaST Based on Partial Preservation of the Lines Alba Cervical","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodule with a maximum diameter not exceeding 6 cm\n* Absence of suspicious lateral lymph nodes or distant metastases\n\nExclusion Criteria:\n\n* Participants with fusion or fixation of lymph nodes in the neck\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of extrathyroidal invasion\n* Participants with a significantly restricted neck and\u002For jaw",{"count":262,"type":22},300,"The investigators have previously proposed a prediction model for difficult transoral and submental thyroidectomy through a retrospective study. In order to better promote transoral and submental endoscopic approach for thyroid surgery and to set up an appropriate training course, the investigators aim to refine the procedure through a prospective study.",[29,265,113],"Thyroid Diseases",[267,268,269],"Endoscopic thyroidectomy","Transoral and submental approach","Prediction model","2026-08-05",{"date":247,"type":37},{"date":273,"type":37},"2024-05-01",{"date":275,"type":22},"2028-12-31",{"name":277,"class":73},"Shanghai 6th People's Hospital",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":45},"100650699","trophoblast-cell-surface-antigen-2-trop-2-targeted-petct-in-recurrent-and-metastatic-thyroid-cancer-100650699","NCT07753499","Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET\u002FCT in Recurrent and Metastatic Thyroid Cancer","Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET\u002FCT in Recurrent and Metastatic Thyroid Cancer and Compared With 68Ga-FAPI PET\u002FCT","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with a history of previously treated thyroid cancer, including DTC and HGFCTC following thyroidectomy with or without 131I therapy, MTC after thyroidectomy, or ATC; either (1) evidence of structural or suspicious lesions on standard of care imaging or (2) biochemical evidence of disease in the absence of structural findings, defined as elevated thyrotropin suppressed thyroglobulin (Tgon ≥1 ng\u002FmL after 131I ablation or ≥5 ng\u002FmL without ablation) with negative anti thyroglobulin antibodies (\\\u003C20 IU\u002FmL) for DTC and HGFCTC or elevated calcitonin (\\>10 pg\u002FmL) for MTC;\n* Patients who had scheduled both 68Ga-MY6349 and 68Ga-FAPI PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* No other anticancer therapy within four weeks prior to PET imaging.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients;\n* Patients with a second primary tumor;\n* The inability or unwillingness of the research participant, parent, or legal representative to provide written informed consent.",{"count":286,"type":22},120,[288],"NA","In this study, we comprehensively evaluated the clinical utility of Trop2 PET\u002FCT (68Ga-MY6349 PET\u002FCT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET\u002FCT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET\u002FCT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET\u002FCT, and the impact on clinical management.",[291,292,29],"Tumor","Solid Tumor",[291,294,295,296,297,298,145],"Thyroid cancer","TENIS","Trop-2","FAP","Diagnosis","2026-08-04",{"date":245,"type":37},{"date":302,"type":22},"2026-08-01",{"date":304,"type":22},"2027-12-31",{"name":306,"class":73},"The First Affiliated Hospital of Xiamen University",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":329,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":253},"100610263","a-study-of-meaning-centered-therapy-for-mexican-adults-with-advanced-cancer-100610263","NCT07225309","A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer","Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer","Patient Eligibility Criteria:\n\nA patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener and suicide risk assessment.\n\nInclusion Criteria:\n\nEMR Criteria\n\n\\- Documentation of Disease\n\n* Pathologically confirmed breast, prostate, colorectal, thyroid, cervix, uteri, or lung - solid tumor cancer (either most recent or new diagnosis)\n\n  * Definition of Disease \\[or Measurable Disease\\]\n* Diagnosed with stages III or IV\n\n  * Prior Treatment\n* Receiving ambulatory care at INCan\n\nSelf-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nEMR Criteria\n\n* Prior Treatment\n\n  * Received psychological or psychiatric care at INCan in the last 3 months\n  * In the judgment of the treating physician, protocol investigators, and\u002For study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For study participation\n  * Diagnosed with a serious psychiatric condition\n\nSelf-Report Criteria\n\n* Received psychological or psychiatric care outside of INCan in the last 3 months\n* Presence of suicide risk determined by the Columbia-Suicide Severity Rating Scale\n* Too ill to participate determined by the question: \"Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?\"\n\nProvider Eligibility Criteria:\n\nInclusion Criteria Self-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded",{"count":262,"type":22},[288],"The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.",[318,319,320,29,321,322,323,324,325,326,327,328],"Breast Cancer","Prostate Cancer","Colorectal Cancer","Breast Cancer Stage III","Breast Cancer Stage IV","Prostate Cancer Stage III","Prostate Cancer Stage IV","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Thyroid Cancer Stage III","Thyroid Cancer Stage IV",[330,331,332,333,334,335,336,337,338,294,339,340,341,342],"Breast cancer","Breast cancer Stage III","Breast cancer Stage IV","Prostate cancer","Prostate cancer Stage III","Prostate cancer Stage IV","Colorectal cancer","Colorectal cancer Stage III","Colorectal cancer Stage IV","Thyroid cancer Stage III","Thyroid cancer Stage IV","25-240","Memorial Sloan Kettering Cancer Center","2026-07-31",{"date":345,"type":37},"2026-08-03",{"date":347,"type":37},"2026-05-01",{"date":349,"type":22},"2029-04-13",{"name":342,"class":73},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":162,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":372},"100466589","phase-1-a-study-to-learn-about-the-study-medicine-called-pf-07799933-in-people-with-advanced-solid-tumors-with-braf-alterations-100466589","NCT05355701","A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS","This study is seeking participants who meet the following key eligibility criteria:\n\nInclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor including primary brain tumor.\n* Qualifying BRAF alteration (V600 or non-V600 Class II\u002FClass III BRAF alteration), in tumor tissue and\u002For blood (ie circulating tumor deoxyribonucleic acid \\[DNA\\], or ctDNA).\n* Disease progressed during\u002Ffollowing last prior treatment and no satisfactory alternative treatment options (Part 1, Part 2 (doublet), and Part 3 (cohorts 2, 3, 6, 7)).\n* Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies\n* Part 3 (Cohort 1) (BRAF V600 mutant melanoma): Prior BRAF V600 inhibitor therapy required, prior MEK inhibitor therapy required, and immune checkpoint inhibitor therapy required.\n* Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required. No prior BRAF inhibitor\u002FEGFR inhibitor allowed. Participants with MSI-H\u002FdMMR mCRC should receive prior immune checkpoint inhibitor therapy.\n* Part 3 (Cohort 5) (BRAF V600E CRC): No more than 2 cycles of prior 5-FU based chemotherapy allowed. No prior BRAF inhibitor\u002FEGFR inhibitors allowed. Participants with MSI-H\u002FdMMR mCRC should receive prior immune checkpoint inhibitor therapy.\n\nExclusion Criteria:\n\n* Brain metastasis larger than 4 cm\n* Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO; history of retinal degenerative disease.\n* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK).",{"count":359,"type":22},267,[25],"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.\n\nThis study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called \"BRAF\" and available treatments are no longer effective in controlling their cancer.\n\nAll participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine:\n\n* People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day.\n* People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV).\n\nParticipants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.",[168,363,29,169,364],"Non-Small-Cell Lung Cancer","Advanced Colorectal Cancer (Part 1)","2026-07-30",{"date":343,"type":37},{"date":368,"type":37},"2022-07-05",{"date":370,"type":22},"2029-10-25",{"name":196,"class":197},40,{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100589830","phase-2-zanzalintinib-for-the-treatment-of-advanced-thyroid-cancer-before-surgery-100589830","NCT06959511","Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery","ZAnzalintinib Neoadjuvant EValuation in Thyroid Oncology (ZANEVO)","Eligibility Criteria\n\n1. Participants with differentiated thyroid cancer, non-RET-mutated medullary thyroid cancer, or poorly differentiated thyroid cancer who present with locoregionally advanced disease, as defined by extrathyroidal and\u002For extra nodal extension, or with advanced recurrent\u002Fresidual invasive\u002Fbulky nodal disease will be enrolled in this trial, regardless of whether distant metastases are present or not.\n2. At least 18 years of age on the day of signing informed consent.\n3. Pathologic findings supporting the clinical impression of papillary thyroid cancer, follicular thyroid cancer, oncocytic thyroid cancer, medullary thyroid carcinoma, and\u002For poorly differentiated thyroid carcinoma. For patients with Bethesda IV or V FNA's (e.g. follicular neoplasm, follicular lesion, Hürthle cell neoplasm, Hürthle cell lesion), if the radiographic context is conclusive for carcinoma of thyroid origin, including significant extrathyroidal extension with invasion of surrounding structures and PET avidity, patients can be enrolled.\n4. Thyroid Neck Group morbidity complexity score of 1 to 4 (moderate, severe, very severe, or unresectable).\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with no known sudden deterioration 2 weeks prior to the first dose of trial treatment.\n6. Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy (e.g., physiological replacement of mineral corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy are permitted.\n7. Adequate organ and marrow function, based upon meeting all the following laboratory criteria within 28 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC)≥ 1500\u002Fmm3 (≥1.5 GI\u002FL) without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection.\n   2. Platelets ≥ 100,000\u002Fmm3 (≥100 GI\u002FL) without transfusion within 2 weeks of screening laboratory sample collection.\n   3. Hemoglobin ≥9 g\u002FdL (≥90 g\u002FL) without transfusion within 2 weeks prior to screening laboratory sample collection.\n   4. International Normalized Ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x ULN. For subjects with documented bone metastasis ALP ≤5 x ULN.\n   6. Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert fs disease ≤ 3 x ULN).\n   7. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40 mL\u002Fmin ( ≥0.67 mL\u002Fsec) using the Cockcroft Gault equation.\n   8. Urine protein-to-creatinine ratio (UPCR) ≤1 mg\u002Fmg ( ≤113.2 mg\u002Fmmol) creatinine.\n8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n9. For MD Anderson site only, subjects must be willing to undergo tumor biopsy prior to trial treatment, unless in the opinion of the treating physician, a biopsy is not feasible or safe. For all sites, subjects must be willing to ultimately undergo surgery if their tumor becomes surgically resectable. Subjects retain the right to refuse any research interventions.\n10. Sexually active fertile subjects and their partners must agree to use highly effective method of contraception (defined in Appendix A) during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods. (1) through 186 days after the last dose of zanzalintinib for women of childbearing potential (WOCBP) or through 96 days after the last dose of zanzalintinib for men.\n11. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n\nExclusion Criteria:\n\n1. Medullary thyroid cancer participants with germline RET or known somatic RET mutations.\n2. Prior treatment with zanzalintinib.\n3. Prior treatment with a tyrosine kinase inhibitor.\n4. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n5. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed.\n7. Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin inhibitors) and platelet inhibitors (e.g., clopidogrel).\n\n   Allowed anticoagulants are the following:\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.\n\n   Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.\n8. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n9. The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Unstable or deteriorating cardiovascular disorders: i. Congestive heart failure New York Heart Association class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes). ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment. iii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant arterial thrombotic and\u002For ischemic event within 6 months before first dose of study treatment.\n\n   iv. Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before to first dose of study treatment. Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Participants who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n10. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n11. Symptomatic cavitating pulmonary lesion(s) or endobronchial disease (asymptomatic or radiated lesions allowed. Intratracheal disease is allowed, as long as the endotracheal disease is not associated with major bleeding episodes.\n12. Lesions invading major blood vessel including, but are not limited to, inferior vena cava, pulmonary artery, or aorta. Note: Subjects with internal jugular vein involvement or tumor thrombus in the neck are eligible. Additionally, subjects with intravascular tumor extension (e.g., tumor thrombus in renal vein or inferior V. cava) may be eligiblefollowing Principal Investigator approval.\n13. Other clinically significant disorders that would preclude safe study participation.\n\n    1. Active infection requiring systemic treatment. Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.\n    2. Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)- related illness except for subjects meeting all of the following criteria: (1) on stable anti-retroviral therapy; (2) CD4+ T cell count ≥ 200\u002FμL; and (3) an undetectable viral load. Note: HIV testing will be performed at screening if and as required by local regulation. Note: To be eligible, participants taking CYP inhibitors (e.g., zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose. Note: CD4+ T cell counts and viral load are monitored per standard of care by the local health care provider.\n    3. Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n    4. Malabsorption syndrome.\n    5. Uncontrolled symptomatic hyperthyroidism or hypothyroidism.\n    6. Uncontrolled symptomatic hypercalcemia or hypocalcemia.\n    7. Moderate to severe hepatic impairment (Child-Pugh B or C).\n    8. Requirement for hemodialysis or peritoneal dialysis.\n    9. History of solid organ or allogeneic stem cell transplant.\n14. Major surgery (as defined in Appendix B; e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to first dose of study treatment. Minor surgery (e.g., simple excision, tooth extraction) within 5 days before first dose of study treatment. Fine needle aspiration and core biopsies are allowed on study drug without drug hold.Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment.\n\n    Note: Participants with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.\n15. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per electrocardiogram (ECG) before first dose of study treatment.\n16. History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.\n17. Pregnant or lactating females.\n18. Inability to swallow tablets or ingest a suspension either orally or by nasogastric (NG) or gastrostomy (PEG) tube.\n19. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n20. Another malignancy that requires active therapy and in the opinion of the Investigator would interfere with monitoring of radiologic assessments of response to Investigational Product, within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.\n21. Other conditions, which in the opinion of the Investigator, would compromise the safety of the participant or the participants ability to complete the study.",{"count":381,"type":22},45,[26],"To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.",[385,29],"Neoadjuvant Treatment","2026-07-24",{"date":388,"type":37},"2026-07-28",{"date":390,"type":37},"2025-07-22",{"date":392,"type":22},"2030-10-01",{"name":394,"class":73},"M.D. Anderson Cancer Center",4,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":4},"100547735","mapping-patient-decision-making-in-thyroid-cancer-100547735","NCT06411834","Mapping Patient Decision-making in Thyroid Cancer","Mapping Patient Decision-making in Thyroid Cancer: Improving Decision Outcomes Through Ethnographic Decision Modeling","Inclusion Criteria:\n\n* Age \\>18\n* Newly diagnosed or suspected thyroid cancer\n\nExclusion Criteria:\n\n* Strong indication for total thyroidectomy\n* tumor size \\>4 cm\n* nodal or distant metastases\n* evidence of extrathyroidal extension\n* Non-English speaking",{"count":404,"type":22},50,[288],"The incidence of thyroid cancer has exploded in the past 5 decades, with a roughly three-fold increase since 1995. Fortunately, many new cases are small, early-stage thyroid cancers. The American Thyroid Association guidelines state that patients with papillary thyroid cancers less than 4 cm can choose either thyroid lobectomy or total thyroidectomy. However, it is unclear why patients will sometimes choose more aggressive treatments that carry additional operative risk when a less aggressive option is available. When investigators examined thyroid specialists' recommendations for thyroid cancer treatment, investigators found significant variation between physicians' risk estimates and their treatment recommendations. This illustrated that patients may receive inconsistent counseling regarding their diagnosis and treatment options from different providers. Worse yet, other studies have shown that patients often do not perceive a choice in their treatment. When patients undergo treatments that do not align with their own priorities and values, they may experience regret and low satisfaction. Decision aids have been shown to help patients feel more educated about their options but have not had an effect on their treatment choice, decision regret, or satisfaction.\n\nThe aim of this study is to use an ethnographic approach to map the patient decision-making process and develop a Decision Navigation Tool to improve decision outcomes for thyroid cancer patients. An ethnographic approach seeks to understand the social norms, culture, and context that influence these decisions. Investigators will do so in 3 phases: 1) elicit patient decision criteria in selecting initial treatment for thyroid cancer, 2) construction and validation of decision-tree model for initial treatment of thyroid cancer, and 3) pilot randomized controlled trial of a Decision Navigation Tool. To construct the decision model, investigators will recruit a diverse sample of patients with varying age, gender, race\u002Fethnicity, and operative and cancer outcomes. The Decision Navigation Tool will highlight patients' values and priorities and empower them to select a treatment aligned with their preferences. This study will provide important insights into the patient experience of decision-making in thyroid cancer and test the feasibility of a future multi-center large-scale clinical trial of a Decision Navigation Tool to improve decision outcomes.",[29],[409],"decision-making","2026-07-22",{"date":386,"type":37},{"date":413,"type":22},"2028-04",{"date":415,"type":22},"2029-06",{"name":417,"class":73},"University of California, Los Angeles",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":21},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":428,"type":22},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[431,432,433,434,435,436,437,438,439,440,168,441,442,443,444,445,319,446,447,448,449,450,451,29,452,453,454],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-07-21",{"date":410,"type":37},{"date":458,"type":37},"2025-09-18",{"date":460,"type":22},"2028-03-30",{"name":462,"class":197},"AstraZeneca",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":478,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":488,"leadSponsor":490,"locationsCount":45},"100647292","effectiveness-of-wechat-supported-neck-rehabilitation-exercises-on-early-recovery-after-thyroidectomy-100647292","NCT07707401","Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy","Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing thyroid surgery\n* Postoperative condition stable, with the attending physician assessing the patient as fit for neck movement\n* Willing to participate in the study, complete scheduled follow-ups, and sign a written informed consent form\n\nExclusion Criteria:\n\n* History of prior thyroid or neck surgery\n* History of cervical spondylosis, cervical spine surgery, neck trauma, or other conditions affecting neck mobility\n* Postoperative complications rendering the patient unsuitable for neck movement training, such as confirmed recurrent laryngeal nerve injury, chyle leak, or complications requiring reoperation or prolonged drainage, or incision infection\n* Persistent postoperative dizziness or other conditions unsuitable for exercise\n* Unable to use WeChat and lacking assistance from family members","60 Years",{"count":472,"type":22},200,[288],"This study aimed to evaluate the effectiveness, safety, and implementation outcomes of a WeChat mini program-supported tele-neck rehabilitation exercises for improving early postoperative neck recovery after thyroidectomy.",[265,29,476,477],"Surgery","Postoperative Pain",[479,480,481,482,118,483],"Tele-exercise program","Telehealth","Health-related quality of life","Postoperative rehabilitation","Neck exercise","2026-07-13",{"date":486,"type":37},"2026-07-16",{"date":484,"type":37},{"date":489,"type":22},"2029-06-30",{"name":277,"class":73},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":519,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":544},"100647234","phase-1-fapi-pet-imaging---an-exploratory-study-100647234","NCT07705074","FAPI PET Imaging - An Exploratory Study","FAPI PET Imaging - a Multicentric Exploratory Evaluation","FAPIPET","Inclusion Criteria:\n\n* Written informed consent obtained and documented by the participant's signature.\n* Age ≥18 years at the time of consent.\n* Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.\n* Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT\u002FMRI) to allow comparative evaluation.\n\nExclusion Criteria:\n\n* Severe claustrophobia that would preclude PET imaging.\n* Inability to remain still for the duration of the PET\u002FMR examination.\n* Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.\n* Previous hypersensitivity reactions to radiotracer administration\n* Inability to understand the study information, for example due to language barriers.\n* Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).\n* Participants scheduled for PET\u002FMR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.",{"count":500,"type":22},770,[25,26],"This study is testing a new imaging tracer called \\[18F\\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.\n\n\\[18F\\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.\n\nPeople who join this study will get one injection of the tracer into a vein, then have one PET\u002FCT or PET\u002FMR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.\n\nThe study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.",[504,505,506,507,29,318,508,509,510,511,512,513,514,515,516,517,518],"Thyroid Pathology","Head and Neck Cancer (H&N)","Sinonasal Tract Tumor","Sarcoidosis","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)","Pancreatic Cancer, Adult","Urothelial Carcinoma (UC)","Multiple Myeloma or Plasmacytoma","Mesothelioma","Hepatic Fibrosis","Endometriosis (Diagnosis)","Lung Fibrosis","Neck Node Metastasis","Prostate Cancer (CRPC)",[520,521,522,145,523,524,525,526,527,528,529,530,531,532,533,534],"[18F]FAPI-74","Fibroblast Activation Protein","FAP-targeted imaging","Radiotracer","Diagnostic imaging","Multicentric study","Radiopharmaceutical","FAPI","FAPI-74","nuclear medicine","University Hospital Zurich","swiss multicenter trial","Cancer-associated fibroblast imaging","oncologic imaging","non-oncologic imaging","2026-07-09",{"date":537,"type":37},"2026-07-15",{"date":539,"type":22},"2026-08",{"date":541,"type":22},"2029-09",{"name":543,"class":73},"Martin Huellner",5,{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":557,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":565,"leadSponsor":567,"locationsCount":4},"100646588","pre-clinic-visit-online-education-for-thyroid-cancer-100646588","NCT07690839","Pre-Clinic Visit Online Education for Thyroid Cancer","A Randomized Controlled Trial Evaluating Educational Resources for Patients With Thyroid Cancer","Inclusion Criteria:\n\n* Newly diagnosed with either:\n\n  1. ≤2cm Bethesda 6 thyroid nodule (papillary thyroid carcinoma) (T1N0)\n  2. ≤2cm Bethesda 5 thyroid nodule\n  3. ≤2cm Bethesda 3-4 thyroid nodule with molecular testing that confers \\>75% risk of malignancy\n* Able to understand and complete questionnaires independently in English\n* Access to an internet-enabled device for online surveys and intervention access\n\nExclusion Criteria:\n\n* Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation\n* Has nodule \\>2cm in size, or with non-papillary thyroid carcinoma histology\n* High-grade or poorly differentiated papillary thyroid carcinoma (PTC) variants\n* Central or lateral neck lymphadenopathy suspicious for PTC\n* Unfavorable nodule location, to be determined by the surgeon (e.g. Near dorsal surface (by recurrent laryngeal nerve); adjacent to trachea (risk of cartilage invasion)\n* Recurrent thyroid cancer case",{"count":553,"type":22},60,[288],"Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online educational resources among adult patients with thyroid cancer. Each online program can be accessed on the patient's personal device, and will be provided to the patient following a diagnosis of thyroid cancer but before meeting with their surgeon to discuss treatment options. The goal of the resource is to educate patients on the various treatment options for thyroid cancer prior to surgical consultation, so that clinic visit time can be better utilized to discuss patient questions and priorities, and support shared decision making. Clinical (TC-MAX; thyroid cancer related anxiety) and behavioral outcomes (decisional conflict, shared-decision making, treatment decision) will be assessed via online surveys 1-day and 14-days post-visit.",[29],[558,559,560],"Online Education","Remote Monitoring","Shared Decision Making","2026-07-02",{"date":563,"type":37},"2026-07-08",{"date":539,"type":22},{"date":566,"type":22},"2027-09",{"name":568,"class":73},"Cedars-Sinai Medical Center",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":576,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":584,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":45},"100624165","navigation-intervention-for-adolescent-and-young-adult-cancer-survivors-100624165","NCT07406087","Navigation Intervention for Adolescent and Young Adult Cancer Survivors","Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors","Inclusion Criteria:\n\n* Received diagnosis of local or regional breast, ovarian, cervical, testicular, colon\u002Frectal, melanoma, endometrial, sarcoma, or thyroid cancer between the ages of 15-39 years (\"index cancer\")\n* Current age 21-45 years\n* Diagnosed and treated for index cancer within Kaiser Permanente Southern California adult medical oncology and\u002For surgery\n* Current Kaiser Permanente insurance coverage\n\nExclusion Criteria:\n\n* Patients with a history of or current diagnosis of leukemia or lymphoma\n* Patients with metastatic disease at diagnosis","21 Years","45 Years",{"count":7,"type":22},[288],"The investigators propose to: 1) Adapt an evidence-based cancer-focused patient navigation (PN) program for the Adolescent and Young Adult (AYA) cancer survivor population; and 2) Plan and conduct an effectiveness-implementation trial of this program within Kaiser Permanente Southern California (KPSC). PLEASE NOTE: This study is awarded in two phases. The UG3 phase has been awarded for the first two years; upon successful completion of this phase by meeting pre-defined milestones, the National Cancer Institute (NCI) will provide funding for the second phase of the study (Years 3-6), which will allow our team to conduct a trial to determine the effectiveness of the implementation of the adapted PN program for the AYA cancer survivor population. This application is focused on the initial UG3 phase and will update the protocol for the UH3 trial upon successful completion of the UG3 milestones and receipt of the UH3 award.\n\nThe primary objectives in the UG3 phase of the study are to adapt and tailor an existing PN program to meet the needs of AYA cancer survivors and the local clinical context via (a) interviews with key stakeholders (patients, clinicians, administrators) and (b) guidance from our AYA Primary Care Survivorship Council. The investigators will conduct a pilot study of the adapted PN program and refine the program to enhance acceptability to patients and clinicians, enhance feasibility and effectiveness, and develop and pilot evaluation tools and methods prior to the start of the UH3 phase of the trial, which will be a larger trial. Objectives will be updated for the UH3 phase once awarded.",[318,444,434,450,582,583,435,448,29],"Colon Rectal Cancer","Melanoma (Skin Cancer)",[585,586,587,588,589],"Adolescent and Young Adult","Cancer Survivors","Patient Navigation","Adaptations","Implementation Science","2026-07-01",{"date":592,"type":37},"2026-07-06",{"date":594,"type":37},"2026-03-15",{"date":596,"type":22},"2027-08",{"name":598,"class":73},"Kaiser Permanente",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":606,"sex":17,"minAge":607,"maxAge":608,"enrollmentInfo":609,"targetDuration":611,"studyType":85,"phases":4,"briefSummary":612,"conditions":613,"keywords":647,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":665},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":610,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[445,29,614,436,615,616,617,618,432,619,620,621,622,440,623,624,625,626,433,627,628,319,450,629,452,630,631,632,633,634,635,636,637,447,638,639,640,513,318,641,168,448,642,643,444,435,453,644,645,646],"Lung Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Kidney Cancer","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[445,29,648,649,650,651,652,653,113,654,318,655,645,646],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":658,"type":37},"2026-06-29",{"date":660,"type":37},"2013-11-01",{"date":662,"type":22},"2099-12",{"name":664,"class":73},"University of Nebraska",42,{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":674,"targetDuration":4,"studyType":23,"phases":676,"briefSummary":678,"conditions":679,"keywords":681,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":692},"100384819","phase-3-systematic-radioiodine-administration-versus-decision-of-radioiodine-treatment-guided-by-a-post-operative-work-up-100384819","NCT04290663","Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up","Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy","INTERMEDIATE","Inclusion Criteria:\n\n* Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined as follows according to TNM 2017:\n\n  * Papillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid cancer (FTC) (with \\\u003C 4 foci of vascular invasion) or Hürthle cell carcinoma (HCC)\n  * T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and\u002For pN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10\n  * T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10\n* Patient treated by total thyroidectomy with macroscopically complete tumor resection (R0 or R1) ± neck dissection\n* Total thyroidectomy performed within 6 to 14 10 weeks before randomization\n* Patient with or without anti-thyroglobulin antibodies (TgAb)\n* No known distant metastases\n* Normal post-operative neck ultrasound (US) or if doubtful US, negative cytology and normal Tg value (\\\u003C10 ng\u002Fml) in FNA washout fluid\n* Post-operative LT4 treatment initiated at least 6 weeks before randomization\n* Performance Status 0 or 1\n* Patients aged 18 years or older\n* Signed informed consent form\n* Patient who agrees to be followed annually during 5 years\n* Patient affiliated to the French social security system\n\nExclusion Criteria:\n\n* • Patients with:\n\n  * medullary or anaplastic thyroid cancer\n  * or poorly differentiated carcinoma\n  * or well differentiated FTC with at least more than 4 foci of vascular invasion\n  * or PTC with aggressive variants (tall cell or columnar cell carcinoma, diffuse sclerosing papillary, hobnail variant)\n  * NIFTP (Noninvasive follicular thyroid neoplasm with papillary-like nuclear features)\n\n    • Low-risk or high-risk DTC patients according to ATA 2015, and intermediate-risk patients with extra-thyroid extension into the perithyroidal muscles (pT3b according to pTNM 2017), and\u002For pN1 with nodal largest dimension \\>10 mm or with extra-capsular invasion or more than 10 metastatic nodes. This excludes the following patients:\n  * All pT1a, pT3 or pT4\n  * pT1aN0\u002Fx with or without minimal extra-thyroid extension\n  * pT1bN0\u002Fx, pT2N0\u002FNx without minimal extra-thyroid extension\n  * pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension \\\u003C2mm\n  * pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension \\>10mm\n  * pT2N0\u002FNx without extra-thyroid extension\n  * pT2N1 without extra-thyroid extension and with nodal largest dimension \\\u003C2mm\n  * pT2N1 without extra-thyroid extension and with nodal largest dimension \\>10mm\n  * Surgery considered as macroscopically incomplete (R2)\n\n    * Patients who have undergone lobectomy only\n    * Post-operative neck US with metastatic lymph-nodes confirmed by cytology or by increased Tg (\\>10 ng\u002Fml) in FNA washout fluid\n    * Drugs affecting thyroid function including iodinated contrast agents in the 6 weeks prior to randomization. Amiodarone should have been stopped at least 1 year before randomization.\n    * Previous RAI treatment for thyroid cancer\n    * Pregnant or lactating women\n    * Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study\n    * Patient deprived of liberty or placed under the authority of a tutor\n    * History of malignancy in the past 3 years, except skin cancer excluding melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and not have shown signs of recurrence for at least 3 years",{"count":675,"type":22},368,[677],"PHASE3","This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy",[29,680],"Intermediate Risk",[682,683],"radioiodine","I131","2026-06-24",{"date":656,"type":37},{"date":687,"type":37},"2020-03-02",{"date":689,"type":22},"2033-02",{"name":691,"class":73},"Centre Francois Baclesse",29,{"id":694,"slug":695,"hasResults":12,"nctId":696,"briefTitle":697,"officialTitle":698,"acronym":4,"eligibilityCriteria":699,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":700,"targetDuration":4,"studyType":23,"phases":701,"briefSummary":702,"conditions":703,"keywords":704,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":708,"lastUpdatePostDateStruct":709,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":716},"100516699","phase-2-a-study-of-avutometinib-and-defactinib-in-people-with-thyroid-cancer-100516699","NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer","Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients","Inclusion Criteria:\n\nCohort A will enroll RAIR, R\u002FM DTC patients with RAF dimer-driven disease.\n\nCohort B will enroll ATC patients with RAF dimer-driven disease.\n\n* Cohort A only: Patients must have pathologically or cytologically confirmed differentiated thyroid cancer of follicular origin (including papillary thyroid carcinoma, follicular thyroid carcinoma, hurthle cell carcinomas, poorly differentiated thyroid carcinoma and their respective variants).\n* Cohort B only: Patients must have anaplastic thyroid carcinoma.\n* Confirmation in a CLIA certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastases) possess at least one of the following genetic alterations: RAS mutation, NF1 mutation, RET rearrangement, NTRK rearrangement, ALK rearrangement, Class 2 or 3 BRAF alterations (non-V600E\u002FK mutations or rearrangements).\n* Cohort A only: Evidence of progressive disease (e.g. presence of new or growing lesion(s) on radiologic imaging and\u002For new or worsening tumor-related symptoms) within 14 months of study enrollment.\n* Cohort A only: Patients must have recurrent or metastatic disease not amenable to curative surgery or radiation.\n* Patients with any number of prior therapies will be eligible.\n* Patients must have RECIST v1.1 measurable disease.\n* Age ≥ 18 years.\n* ECOG performance status of 0 or 1.\n* For Cohort A only: Patients must have not had recent treatment for thyroid cancer as defined as:\n\n  * No prior RAI therapy is allowed \\\u003C6 months prior to initiation of therapy on this protocol. A diagnostic study using \\\u003C10 mCi of RAI is not considered RAI therapy\n  * No external beam radiation therapy \\\u003C1 weeks prior to initiation of therapy on this protocol.\n  * No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed \\\u003C4 weeks prior to the initiation of therapy on this protocol\n* For Cohort A only: Patients must have RAI-refractory disease, defined as one of the following:\n\n  * Total lifetime dose of radioiodine \\> 600 mCi\n  * A tumor that is not radioiodine-avid on a diagnostic radioiodine scan performed\n  * A radioiodine-avid metastatic lesion which progressed despite radioiodine treatment given 6 months or more prior to study entry in the study. There are no size limitations for the index lesions used to satisfy this entry criterion\n  * The presence of at least one fluorodeoxyglucose (FDG) avid lesion.\n* Patients must be able to swallow and retain orally-administered pills without any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels.\n* Adequate recovery from toxicities related to prior treatments to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade ≤ 2.\n* Patients must have tissue from the primary tumor or metastases available for correlative studies. Either a paraffin block or at least 20 unstained slides are acceptable (30 unstained slides would be ideal). (If less than twenty unstained slides are available and a paraffin bloc is not available, the patient may be able to participate at the discretion of the investigator).\n* Patients must agree to undergo two research biopsies of (a) malignant lesion(s). Tumor tissue obtained prior to study consent or treatment as part of standard of care can also be submitted in lieu of performance of the first pre-treatment biopsy if the Principal Investigator deems it to be of sufficient quantity\u002Fquality\u002Ftimeliness. Patients may also be exempt from biopsy if 1) the investigator or person performing the biopsy judges that no tumor is accessible for biopsy, 2) the investigator or person performing the biopsy feels that the biopsy poses too great of a risk to the patient (including if conduct of the biopsy will result in an unacceptable delay in therapy), or 3) the patient cannot be safely removed from anti-coagulation therapy (if the anti-coagulation therapy needs to be temporarily held for the biopsy procedure). If the only tumor accessible for biopsy is also the only lesion that can be used for RECIST v1.1 response evaluation, then the patient may be exempt from biopsy. If the investigator deems a second research biopsy to be high risk after a patient has completed the first research biopsy, the patient may be exempt from the second biopsy. Biopsies of lesions that are in proximity to any vital neurovascular structures that can be considered high risk procedures will not be biopsied.\n* Baseline QTc interval \\\u003C 460 ms for women and ≤450 ms for men using Frederica's QT correction formula. NOTE: This criterion does not apply to patients with a right or left bundle branch block.\n* Adequate cardiac function wit left ventricular ejection fraction \\>50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan.\n* Screening laboratory values must meet the following criteria:\n\n  * WBC ≥ 2000\u002FμL\n  * Neutrophils ≥ 1000\u002FμL\n  * Platelets ≥ 100 x10\\^3 \u002FμL\n  * Hemoglobin \\> 9.0 g\u002FdL\n  * AST\u002FALT ≤ 2.5 x ULN (of \\\u003C 5x ULN in patients with liver metastases)\n  * Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\\u003C 3.0 mg\u002FdL)\n  * International normalized ratio (INR) \\\u003C 1.5 and partial thromboplastin time (PTT) \\\u003C 1.5 x ULN in the absence of anticoagulation or therapeutic levels in the presence of anticoagulation.\n  * Albumin ≥ 3.0 g\u002FdL (451 μmole\u002FL)\n  * Creatine phosphokinase (CPK) ≤ 2.5 x ULN\n  * Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 50 mL\u002Fmin (if using the Cockcroft-Gault formula below)\n  * Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg\u002FdL\n  * Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg\u002FdL\n\nExclusion Criteria:\n\n* Symptomatic untreated brain or leptomeningeal metastases Note: Patients with asymptomatic or treated brain or leptomeningeal metastases are allowed. Participants with symptomatic brain or leptomeningeal metastases after surgical and\u002Forg radiation therapy may be allowed with Principal Investigator approval.\n* Prior therapy with a MEK 1\u002F2 inhibitor or an inhibitor that targets Class II\u002FClass III BRAF alterations or a FAK inhibitor (with the exception of patients who received these therapies for a defined period of time to enhance radioiodine activity).\n* Patient who have had systemic investigational anti-cancer therapy within 4 weeks of the first dose of study therapy.\n* Major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or radiotherapy within 1 week of the first dose of study drug.\n* Treatment with warfarin. Patients on warfarin for deep vein thrombosis\u002Fpulmonary embolism should be converted to low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs).\n* Concomitant use of strong inhibitors and inducers of CYP3A4 (see Appendix 1 in Section 18). Patients should refrain from consumption of grapefruit, grapefruit juice and St. John's Wort, and other medications (with or without prescriptions), supplements, herbal remedies or foods that are strong inhibitors or inducers of CYP3A4 during treatment\n* Concomitant use of strong CYP2C9 inhibtors or inducers. For additional guidance see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-druginteractions-table-substrates-inhibitors-and-inducers\n* Concomitant use of strong P-glycoprotein(P-gp) inhibitors or inducers. For additional guidance see https:\u002F\u002Fwww.uptodate.com\u002Fcontents\u002Fimage\u002Fprint?imageKey=EM%2F73326\\&topicKey=HEME%2F1370\\&source=outlinelink\n* Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes.\n* Patients with a history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, such as an intraocular pressure \\> 21 mmHg\n* Treatment-refractory hypertension defined as a blood pressure of systolic \\>140 mmHg and\u002For diastolic \\>90 mmHg which cannot be controlled by anti-hypertensive therapy.\n* Patients with active hepatitis B infection (HBV surface antigen positive).\n* Subject is known to be positive for Human Immunodeficiency Virus (HIV) or active Hepatitis C Virus (HCV). Testing for HIV or Hepatitis C prior to initiation of the study drug is not required. If a patient has a known history of treated HCV, then a viral load is required to confirm clearance of infection.\n* Known severe acute respiratory syndrome coronavirus 2 SARS-Cov2 infection (clinical symptoms) ≤28 days prior to first dose of study therapy.\n* History of rhabdomyolysis.\n* Concurrent congestive heart failure, prior history of class III\u002F IV cardiac disease (New York Heart Association \\[NYHA\\]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive pulmonary disease.\n* Subjects with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease\n* Any other medical condition (e.g., cardiac, gastrointestinal, pulmonary, psychiatric, neurological, genetic, etc.) that in the opinion of the Investigator places the patient at unacceptably high risk for toxicity.\n* Patients who are pregnant or breastfeeding.\n* Patients with hypersensitivity to mannitol, magnesium stearate, HPMC (hydroxypropyl methylcellulose) shells",{"count":140,"type":22},[26],"The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects. Funding Source- FDA OOPD.",[29],[705,706,707],"Avutometinib","Defactinib","23-007","2026-06-18",{"date":710,"type":37},"2026-06-22",{"date":712,"type":37},"2023-08-16",{"date":714,"type":22},"2027-08-16",{"name":342,"class":73},7,{"id":718,"slug":719,"hasResults":12,"nctId":720,"briefTitle":721,"officialTitle":722,"acronym":4,"eligibilityCriteria":723,"healthyVolunteers":12,"sex":17,"minAge":724,"maxAge":4,"enrollmentInfo":725,"targetDuration":4,"studyType":23,"phases":727,"briefSummary":728,"conditions":729,"keywords":730,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":732,"lastUpdatePostDateStruct":733,"startDateStruct":734,"completionDateStruct":736,"leadSponsor":738,"locationsCount":45},"100589951","phase-2-comparison-of-i-124-petct-for-the-diagnosis-of-thyroid-cancer-100589951","NCT06961084","Comparison of I-124 PET\u002FCT for the Diagnosis of Thyroid Cancer","Comparison of I-124 PET\u002FCT to I-123 Whole Body Imaging for the Diagnosis of Thyroid","Inclusion Criteria:\n\n1. Age \\>= 13 years.\n2. Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.\n3. Meeting criteria for one of the following two populations:\n\n   1. American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.\n   2. Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.\n4. Undergone total thyroidectomy.\n5. Planned I-123 imaging within 45 days after enrollment.\n6. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.","13 Years",{"count":726,"type":22},62,[26],"Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.",[29],[731],"Imaging Studies","2026-06-16",{"date":708,"type":37},{"date":735,"type":37},"2025-12-04",{"date":737,"type":22},"2028-04-01",{"name":739,"class":73},"Thomas Hope",{"id":741,"slug":742,"hasResults":12,"nctId":743,"briefTitle":744,"officialTitle":745,"acronym":4,"eligibilityCriteria":746,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":747,"targetDuration":4,"studyType":23,"phases":749,"briefSummary":750,"conditions":751,"keywords":780,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":732,"lastUpdatePostDateStruct":799,"startDateStruct":801,"completionDateStruct":803,"leadSponsor":805,"locationsCount":807},"100499720","phase-1-phase-12-trial-of-s241656-in-selected-rasmapk-mutation--positive-malignancies-100499720","NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies","A Phase 1\u002F2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS\u002FMAPK Mutation-Positive Malignancies","Key Inclusion Criteria:\n\n* Life expectancy of ≥ 12 weeks in the opinion of the investigator.\n* Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.\n* Adequate bone marrow and organ function.\n* Recovered from toxicity to prior anti-cancer therapy.\n\nPart 1 Dose Escalation cohort ONLY:\n\n* Part 1A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations\n* Part 1B: Advanced\u002Fmetastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1C: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 1E: Other advanced\u002Fmetastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations\n\nPart 2 Dose Optimization and Expansion cohorts ONLY:\n\n* Part 2A: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations and\u002For BRAF mutations\n* Part 2A1: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C mutations\n* Part 2A2: Advanced\u002Fmetastatic NSCLC with BRAF mutations\n* Part 2A3: Advanced\u002Fmetastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease\n* Part 2A4: Advanced\u002Fmetastatic NSCLC with a KRAS G12C mutation\n* Part 2B1: Advanced\u002Fmetastatic PDAC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B2: Advanced\u002Fmetastatic CRC with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n* Part 2B3: Advanced\u002Fmetastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations or alterations\n\nKey Exclusion Criteria:\n\n* Cancer that has a known MEK1\u002F2 mutation.\n* Known allergy\u002Fhypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.\n* Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial.\n* Major surgery within 4 weeks of study entry or planned during study.\n* Ongoing anticancer therapy.\n* Ongoing radiation therapy.\n* Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\n* Clinically significant cardiovascular disease.\n* Symptomatic spinal cord compression.\n* Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\n* Females who are pregnant or breastfeeding.\n* Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\n* Prior use of experimental agents that target the KRAS\u002FBRAF\u002FMEK\u002FERK pathway.",{"count":748,"type":22},554,[25,26],"BDTX-4933-101 is a first-in-human, open-label, Phase 1\u002F2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced\u002Fmetastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced\u002Fmetastatic NSCLC with KRAS and\u002For BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and\u002For CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.",[752,753,754,755,756,757,758,182,759,760,761,762,763,292,764,765,766,767,768,29,769,320,770,771,772,773,774,775,776,777,778,779],"Non-small Cell Lung Cancer","Histiocytic Neoplasm","Histiocytosis","BRAF Gene Mutation","BRAF V600E","BRAF V600 Mutation","BRAF Mutation-Related Tumors","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","Recurrent Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma","NSCLC","Solid Carcinoma","KRAS G12D","KRAS G12V","KRAS Mutation-Related Tumors","NRAS Gene Mutation","Thyroid Carcinoma","Colorectal Carcinoma","Recurrent Histiocytic and Dendritic Cell Neoplasm","Brain Metastases","Recurrent NSCLC","KRAS G13C","Acquired Resistance to KRAS G12C Inhibitor","KRAS G12A","KRAS G12F","KRAS G12R","KRAS G13D",[781,782,783,784,785,786,787,788,789,185,790,791,792,793,794,795,796,797,798],"BRAF Class I","BRAF Class II","BRAF Class III","KRAS","Intolerant histiocytic neoplasm","BDTX-4933","Phase 1","dose escalation","dose expansion","mitogen-activated protein kinase","RAS","RAF","Upstream oncogenic alterations","RAF inhibitor","intracranial disease","CRAF","NRAS","RAF fusions",{"date":800,"type":37},"2026-06-17",{"date":802,"type":37},"2023-04-18",{"date":804,"type":22},"2028-06",{"name":806,"class":73},"Institut de Recherches Internationales Servier",27,{"id":809,"slug":810,"hasResults":12,"nctId":811,"briefTitle":812,"officialTitle":813,"acronym":4,"eligibilityCriteria":814,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":815,"targetDuration":817,"studyType":85,"phases":4,"briefSummary":818,"conditions":819,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":820,"lastUpdatePostDateStruct":821,"startDateStruct":822,"completionDateStruct":824,"leadSponsor":826,"locationsCount":45},"100452547","environmental-factors-and-thyroid-cancer-100452547","NCT05172921","Environmental Factors and Thyroid Cancer","The Role of Environmental Factors in Thyroid Cancer","Inclusion criteria:\n\n* Bethesda category III, IV, V or VI following Fine Needle Aspiration; if a patient has a benign tumor following surgery, patient data\u002F samples will be stored to serve as benign control in potential future projects.\n* Age 18 years and older\n* Surgical candidate\n* Ability to provide informed consent\n\nExclusion criteria:\n\n* History of thyroid cancer\n* Completion surgery candidate\n* Pregnant women or other vulnerable patients (e.g. wards of the state, prisoners)",{"count":816,"type":22},500,"4 Years","Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's in the US and worldwide. Early detection of small, papillary thyroid cancers using high quality diagnostic imaging explains only about 50% of this increased incidence, suggesting that there is a true increase in the occurrence of thyroid cancer and that changes in the prevalence of environmental risk factors might play a role in thyroid cancer etiology and progression. Yet, the cascade of environmental triggers linked to thyroid cancer remains elusive.\n\n'Exposomics' studies all health relevant chemical exposures that an individual experiences, and leverages metabolomic platforms to estimate the \"internal\" environment, informing both exogenous exposures and the metabolic products that lead to, or arise from, disease. Besides exposure to ionizing radiation as known modifiable risk factor, epidemiological evidence suggests that exposure to endocrine disrupting chemicals may be a potential thyroid cancer risk factor due to their known effects on thyroid function. However, these studies relied either on exposure questionnaires which are susceptible to recall bias, or used a limited set of targeted biomarkers measured after diagnosis for testing associations with case-control status, and not thyroid cancer prognosis. Further, the molecular basis for observed associations with thyroid cancer remains unclear.\n\nTo address the overall hypothesis that environmental exposures alter metabolic pathways and therefore affect thyroid cancer prognosis, small amounts of blood will be collected using dried blood microsampler technology (e.g. Mitra® sampling devices), which is minimally invasive and can be used to collect repeated blood measurements at home, without the need for specialized training. These dried blood samples will be used to perform metabolomics experiments, which describe the sum of exogenous exposures, metabolic alterations, and biological response. Additional exposure assessment will be performed using an exposure questionnaire. These results will be associated with thyroid cancer prognosis, e.g. disease-specific survival, disease recurrence, and mutational profiles, thus investigating the role of environmental exposures in the development of more aggressive forms of thyroid cancer.",[29],"2026-06-15",{"date":800,"type":37},{"date":823,"type":37},"2022-02-03",{"date":825,"type":22},"2035-06",{"name":827,"class":73},"Icahn School of Medicine at Mount Sinai"]